Please login to the form below
Antares appoints David Bergstrom as SVP
Second major appointment in one month
Antares Pharma has appointed Dr David Bergstrom as senior VP of pharmaceutical development.
Dr Bergstrom joins from Advantar Laboratories where he serves as executive VP and chief operating officer.
His previous roles included spells as chief operating office of NoveDel Pharmaceuticals and general manager of pharmaceutical development at Cardinal Health.
He is the second senior VP to join Antares this month after the appointment of former Pfizer VP Dr Bruce Freundlich as senior VP, medical.
The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.
Dr Paul Wotton, CEO of Antares, said: "David has a proven track record as a leader of product development teams and has worked on multiple FDA approved products including 505B2 drug/device combination programmes. His broad product development expertise will help drive our pipeline initiative."
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine
- Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics
- Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Vir Biotech launches new research programme for HIV and malaria prevention
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- After the wildfire: how will healthcare recover from the pandemic?
- The New Normal: Upcoming Trends in Clinical Trials
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Keytruda monotherapy fails in triple negative breast cancer
- Assessing the value of interim analyses in clinical trials
- Pfizer's 2021 revenue predictions soar to $82bn
- NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
- A rare talent
PMHub
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...
Latest intelligence
- The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
- Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
- How to innovate and influence people in times of misinformation
- The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
- Could femtech be the answer to the gender health gap?
- Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...
